SP-MHCI-0579-3

Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

US$507.00

In stock

Description

About Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

The Human Papillomavirus (HPV) 16 Protein E7 Peptide (IEDB: 64818) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Protein E7 Peptide, H-TLGIVCPI-OH (Uniprot: P03129 aa: 86-93) from JPT is produced under strict quality control and quality management.

Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI - Specifications

  • Peptide sequence: H-TLGIVCPI-OH
  • Amount: 10 mg (10 x 1 mg)
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Infection
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Peptide Synthesis Services!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

References:
Read References with JPT’s Antigen Peptides
Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI has been described in:
Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope., Cancer Res, 1996 (PMID: 8564975)
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice., Cancer Res, 2002 (PMID: 12384540)
Structural and regulatory diversity shape HLA-C protein expression levels., Nat Commun, 2017 (PMID: 28649982)

Documentation

Documentation for Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

Properties

Properties of Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Infection
Layout: Freeze-dried in glass vial
Organism: Human Papillomavirus (HPV)
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Human papillomavirus type 16 Protein E7 86-93, TLGIVCPI

Information Values
Sequence: H-TLGIVCPI-OH
Specifications: 8mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote